"Hydrochlorothiazide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
| Descriptor ID |
D006852
|
| MeSH Number(s) |
D02.886.590.700.135.261.476 D02.886.655.500.261.476 D03.633.100.174.261.476
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydrochlorothiazide".
Below are MeSH descriptors whose meaning is more specific than "Hydrochlorothiazide".
This graph shows the total number of publications written about "Hydrochlorothiazide" by people in this website by year, and whether "Hydrochlorothiazide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2002 | 3 | 0 | 3 |
| 2003 | 1 | 0 | 1 |
| 2005 | 4 | 0 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 1 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 4 | 5 |
| 2013 | 3 | 1 | 4 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 4 | 0 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydrochlorothiazide" by people in Profiles.
-
Circulating microRNA Biomarkers of Thiazide Response in Hypertension. J Am Heart Assoc. 2024 Feb 20; 13(4):e032433.
-
Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients. Clin Transl Sci. 2022 12; 15(12):2858-2867.
-
Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone. Am J Med. 2021 07; 134(7):918-925.e2.
-
Cutaneous T-cell lymphoma after chronic exposure to hydrochlorothiazide: pharmacovigilance analysis from the RADAR (Research on Adverse Drug events And Reports) Program. J Eur Acad Dermatol Venereol. 2021 Feb; 35(2):e106-e108.
-
Zinc deficiency induces hypertension by promoting renal Na+ reabsorption. Am J Physiol Renal Physiol. 2019 04 01; 316(4):F646-F653.
-
Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. Am J Cardiol. 2018 11 01; 122(9):1496-1505.
-
A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. J Hypertens. 2018 04; 36(4):947-956.
-
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses). Circ Genom Precis Med. 2018 04; 11(4):e001854.
-
Newly Diagnosed Meniere's Disease: Clinical Course With Initiation of Noninvasive Treatment Including an Accounting of Vestibular Migraine. Ann Otol Rhinol Laryngol. 2018 May; 127(5):331-337.
-
Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. J Clin Hypertens (Greenwich). 2018 04; 20(4):694-702.